177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response.
We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after underg
APA
Raeisi N, Saber Tanha A, et al. (2025). 177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response.. Clinical nuclear medicine, 50(5), e315-e316. https://doi.org/10.1097/RLU.0000000000005728
MLA
Raeisi N, et al.. "177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response.." Clinical nuclear medicine, vol. 50, no. 5, 2025, pp. e315-e316.
PMID
40179304
Abstract
We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after undergoing a single cycle of 177Lu-FAPI-2286 therapy. A pretreatment 99mTc-FAPI-46 scan showed diffuse uptake throughout both lungs and subsequent serial post-treatment scans demonstrated sustained uptake in pulmonary metastases. After treatment, there was a significant decline in serum thyroglobulin levels, accompanied by a remarkable improvement in symptoms, leading to near-complete resolution. This case highlights the potential of 177Lu-FAPI-2286 therapy as an effective treatment option for RAIR PTC patients.
MeSH Terms
Humans; Male; Adult; Thyroid Neoplasms; Thyroid Cancer, Papillary; Iodine Radioisotopes; Carcinoma, Papillary; Treatment Outcome; Carcinoma; Lutetium; Radioisotopes
같은 제1저자의 인용 많은 논문 (4)
- Superior Diagnostic Performance of 99mTc-FAPI-46 SPECT/CT Versus 18FDG PET/CT in Detecting Peritoneal Involvement in Mucinous Adenocarcinoma of the Colon.
- 99m Tc-FAPI-46 Uptake in Medication-Related Jaw Osteonecrosis.
- 177Lu-FAPI-2286 Therapy in Metastatic Breast Cancer: A Case Study Highlighting the Potential Risk of Tumor Dedifferentiation and Hormonal Marker Elevation.
- Prostate Adenocarcinoma Recurrence in the Vas Deferens Unveiled by 99m Tc-PSMA SPECT/CT Imaging.